SEC Form 4 · accession 0000899243-19-002872
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C. Davis Jr.
Officer — Chief Medical Officer
Period of report
Feb 5, 2019
Accepted (ET)
Feb 7, 2019 · 4:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001690585
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.13 | Feb 5, 2019 | A | 70,000 | A | — | Feb 4, 2029 | Common Stock | 70,000 | 70,000 | D |
Explanation of responses
- F1This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019.